Latest Articles

Publication Date
Effect of Endometriosis on Disease-Specific Quality of Life.

To evaluate disease-specific quality of life (QOL) in women with endometriosis and assess concurrent validity of the Endometriosis Impact Questionnaire (EIQ).

Published: March 20, 2025, midnight
Glypican3 and serglycin as potential biomarkers involved in the pathogenesis of ovarian endometriosis.

Endometriosis, a non-malignant gynecological disorder characterized by debilitating symptoms, displays several cancer-like characteristics, including metastatic behavior and extracellular matrix (ECM) remodeling. The dynamics of ECM are largely influenced by proteoglycans …

Published: March 20, 2025, midnight
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - The Malaysian Reserve

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy The Malaysian …

Published: March 19, 2025, 10:53 p.m.
ESSE Care Aims to Transform Endometriosis Care by Launching a Year-Long Initiative That Brings Together Patients and Experts Worldwide - ACCESS Newswire

ESSE Care Aims to Transform Endometriosis Care by Launching a Year-Long Initiative That Brings Together Patients and Experts Worldwide ACCESS Newswire

Published: March 19, 2025, 12:02 p.m.
NHS approval of endometriosis therapy Ryeqo enhances patient care - The Hippocratic Post

NHS approval of endometriosis therapy Ryeqo enhances patient care The Hippocratic Post

Published: March 19, 2025, 12:01 p.m.
ESSE Care Aims to Transform Endometriosis Care by Launching a Year-Long Initiative That Brings Together Patients and Experts Worldwide - Newswire

ESSE Care Aims to Transform Endometriosis Care by Launching a Year-Long Initiative That Brings Together Patients and Experts Worldwide Newswire

Published: March 19, 2025, noon
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Weekly Voice

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Weekly Voice

Published: March 19, 2025, 11:20 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Canada Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Canada …

Published: March 19, 2025, 11 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Finance

Published: March 19, 2025, 11 a.m.
Analysis of risk factors for recurrence after laparoscopic myomectomy: A retrospective study.

At present, there is unclear on the risk factors of recurrence after myomectomy. In this study, we hope to provide reference for the choice of treatment for patients with uterine …

Published: March 19, 2025, 12:17 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!